{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Diseases&page=37",
    "query": {
      "condition": "Congenital Diseases",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 10533,
    "total_pages": 1054,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Diseases&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Diseases&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T17:29:39.425Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05967351",
      "title": "A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 400,
      "start_date": "2023-09-27",
      "completion_date": "2033-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 22,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05967351"
    },
    {
      "nct_id": "NCT01412151",
      "title": "Creatine Safety & Tolerability in Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease (HD)"
      ],
      "interventions": [
        {
          "name": "Creatine monohydrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2005-04",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01412151"
    },
    {
      "nct_id": "NCT03224351",
      "title": "A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-659",
          "type": "DRUG"
        },
        {
          "name": "TEZ/IVA",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to VX-659/TEZ/IVA)",
          "type": "DRUG"
        },
        {
          "name": "TEZ",
          "type": "DRUG"
        },
        {
          "name": "VX-561",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to VX-659/TEZ/VX-561)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2017-08-08",
      "completion_date": "2018-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-04-22",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 25,
      "location_summary": "New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morton Grove",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03224351"
    },
    {
      "nct_id": "NCT05676034",
      "title": "AMX0035 in Adult Patients With Wolfram Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wolfram Syndrome"
      ],
      "interventions": [
        {
          "name": "AMX0035",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amylyx Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-03-03",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05676034"
    },
    {
      "nct_id": "NCT02498652",
      "title": "Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "RDEA3170 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "allopurinol 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-07-28",
      "completion_date": "2016-06-02",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • DeLand, Florida • South Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498652"
    },
    {
      "nct_id": "NCT03944447",
      "title": "Outcomes Mandate National Integration With Cannabis as Medicine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain",
        "Chronic Pain Syndrome",
        "Chronic Pain Due to Injury",
        "Chronic Pain Due to Trauma",
        "Fibromyalgia",
        "Seizures",
        "Hepatitis C",
        "Cancer",
        "Crohn Disease",
        "HIV/AIDS",
        "Multiple Sclerosis",
        "Traumatic Brain Injury",
        "Sickle Cell Disease",
        "Post Traumatic Stress Disorder",
        "Tourette Syndrome",
        "Ulcerative Colitis",
        "Glaucoma",
        "Epilepsy",
        "Inflammatory Bowel Diseases",
        "Parkinson Disease",
        "Amyotrophic Lateral Sclerosis",
        "Chronic Traumatic Encephalopathy",
        "Anxiety",
        "Depression",
        "Insomnia",
        "Autism",
        "Opioid-use Disorder",
        "Bipolar Disorder",
        "Covid19",
        "SARS-CoV Infection",
        "COVID-19",
        "Corona Virus Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Cannabis, Medical",
          "type": "DRUG"
        },
        {
          "name": "RYAH-Medtech Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "OMNI Medical Services, LLC",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 200000,
      "start_date": "2018-12-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 17,
      "location_summary": "Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944447"
    },
    {
      "nct_id": "NCT02567292",
      "title": "Human Milk for Congenital Gastrointestinal Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Congenital Gastrointestinal Disorders"
      ],
      "interventions": [
        {
          "name": "Human Milk",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "1 Minute to 1 Year"
      },
      "enrollment_count": 151,
      "start_date": "2018-07-26",
      "completion_date": "2022-01-18",
      "has_results": false,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02567292"
    },
    {
      "nct_id": "NCT00157092",
      "title": "Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha1-antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Aerosolized, Recombinant Alpha 1-Antitrypsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2004-03-01",
      "completion_date": "2004-10-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157092"
    },
    {
      "nct_id": "NCT00093171",
      "title": "Study Evaluating rFIX; BeneFIX® in Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rFIX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": null,
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2009-08-21",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093171"
    },
    {
      "nct_id": "NCT00668187",
      "title": "A Natural History Study of the Gangliosidoses",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tay-Sachs Disease",
        "Sandhoff Disease",
        "Late Onset Tay-Sachs Disease",
        "GM1 Gangliosidosis",
        "GM2 Gangliosidosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 52,
      "start_date": "2010-12",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-16T17:29:39.425Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00668187"
    }
  ]
}